Assembly Biosciences (ASMB) Return on Capital Employed (2011 - 2026)

Assembly Biosciences' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 6.4% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 6505.0% year-over-year to 6.4% in Q1 2026; TTM through Mar 2026 was 6.4%, a 6505.0% increase from a year earlier, with the FY2025 full-year figure at 8.68%, up 4796.0% from the prior year.
• Return on Capital Employed retreated to 6.4% in Q1 2026 per ASMB's latest filing, from 6.06% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 6.06% in Q4 2025 and bottomed at 144.45% in Q3 2023.
• The 5-year median for Return on Capital Employed is 77.38% (2022), against an average of 81.25%.
• Across the five-year window, Return on Capital Employed sank 6905 bps in 2022 and soared 7426 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 98.69% in 2022, then decreased by 19 bps to 117.54% in 2023, then jumped by 38 bps to 73.36% in 2024, then jumped by 92 bps to 6.06% in 2025, then dropped by 6 bps to 6.4% in 2026.
• Per Business Quant, the three latest ASMB Return on Capital Employed figures stand at 6.4% (Q1 2026), 6.06% (Q4 2025), and 40.6% (Q3 2025).